Regenerative Medicine Industry Growing Strong In 2016
The Alliance for Regenerative Medicine (ARM) released its quarterly report in early May, and the numbers look promising. The data gleaned from an in-depth look at close to 700 gene therapy and cell therapy stakeholders in the regenerative medicine sector shows the trends and metrics from the first quarter of 2016.
The ARM is an international advocacy organization based in Washington, D.C., whose multiple stakeholders promote advances in regenerative medicine around the world by encouraging legislation, regulation, and reimbursement to aid the industry. The alliance also works to increase public awareness about regenerative medicine and gene therapy. It supports the growth of its member companies with investor outreach programs and business development services. Since 2009, the ARM has worked to promote the interests of the entire regenerative medicine community in Washington D.C., encompassing the specific interests of 240 members comprised of patient groups, gene therapy companies, research institutions, and investors.
Produced in partnership with Informa, the ARM’s Q1 2016 data report includes industry-specific metrics and statistics on worldwide finances, partnerships, clinical trials, and key events from the stakeholders’ perspective—keeping the alliance’s current priorities in legislation and regulation in mind. Some interesting statistics which emerged include:
- Despite global financial markets battling a downturn, the regenerative medicine sector raised $1.2 billion in Q1 of 2016 towards the advancement of gene and cellular therapies.
- Approximately $520 million were raised in Q1 toward gene and gene-modified cell therapy alone.
- Tissue engineering saw funding of $48.2 million in the first quarter of 2016.
- Investors committed $766.8 million toward cell therapy during this time period.
- Total financings in the European Union were $65.4 million.
- Mergers and acquisitions account for the maximum financings, followed by IPOs, corporate partnerships, follow-ons, and private equity.
- At the close of the quarter, 669 clinical trials were underway around the world, of which 200 are in phase I, 401 are in phase II, and 68 are in phase III.
- Nearly 40 percent of clinical trials currently underway are in the field of oncology.
- Cardiovascular medicine accounts for 12 percent of clinical trials (76 in number).
- There are 51 trials underway in infectious diseases, 47 in conditions of the central nervous system, 39 in musculoskeletal conditions, 36 in dermatology, 33 in ophthalmology, 27 in immunology and inflammation, 16 in gastroenterology, 15 in hematology, 9 in surgery, and a few each in genitourinary diseases, respiratory conditions, ear diseases, and lymphatic diseases.
The diverse membership base of the ARM is made up of university-based research groups, investors in regenerative medicine, patient advocacy groups, non-profit research institutions, and pharmaceutical companies involved in research in this field.
Moving into the second quarter of 2016, the ARM plans to focus on reimbursement policies, optimizing and streamlining drug development and review procedures, a convergence of regulations at an international level, reauthorization by PDUFA, and a Standards Coordinating Body initiative.
The Q1 2016 data report will be followed by new reports at the close of each quarter that will track the performance of various arms in the regenerative medicine sector and provide key financial numbers and clinical trial information as well as highlight the significant clinical events that have taken place or are anticipated.
References:
http://www.marketwired.com/press-release/alliance-regenerative-medicine-releases-q1-2016-data-report-highlighting-sector-trends-2120745.htm
http://alliancerm.org/
Image courtesy of http://www.bitlifesciences.com/
